Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Identifieur interne : 000456 ( PubMed/Curation ); précédent : 000455; suivant : 000457Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Auteurs : Anke A. Dijkstra [Pays-Bas] ; Pieter Voorn ; Henk W. Berendse ; Henk J. Groenewegen ; Annemieke J M. Rozemuller ; Wilma D J. Van De BergSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
Descripteurs français
- Wicri :
- geographic : Pays-Bas.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Analysis of Variance, Case-Control Studies, Cell Count, Cell Death, Disease Progression, Female, Humans, Lewy Body Disease (pathology), Male, Netherlands, Neurons (metabolism), Neurons (pathology), Parkinson Disease (pathology), Severity of Illness Index, Statistics as Topic, Substantia Nigra (pathology), alpha-Synuclein (metabolism).
- MESH :
- chemical , metabolism : alpha-Synuclein.
- geographic : Netherlands.
- metabolism : Neurons.
- pathology : Lewy Body Disease, Neurons, Parkinson Disease, Substantia Nigra.
- Aged, Aged, 80 and over, Analysis of Variance, Case-Control Studies, Cell Count, Cell Death, Disease Progression, Female, Humans, Male, Severity of Illness Index, Statistics as Topic.
Abstract
To gain a better understanding of the significance of α-synuclein pathological conditions during disease progression in Parkinson's disease, we investigated whether 1) nigral neuronal loss in incidental Lewy body disease and Parkinson's disease donors is associated with the local burden α-synuclein pathological conditions during progression of pathological conditions; 2) the burden and distribution of α-synuclein pathological conditions are related to clinical measures of disease progression. Post-mortem tissue and medical records of 24 Parkinson's disease patients, 20 incidental Lewy body disease donors, and 12 age-matched controls were obtained from the Netherlands Brain Bank for morphometric analysis. We observed a 20% decrease in nigral neuronal cell density in incidental Lewy body disease compared with controls. Nigral neuronal loss (12%) was already observed before the appearance α-synuclein aggregates. The progression from Braak α-synuclein stage 3 to 4 was associated with a significant decline in neuronal cell density (46%). Nigral neuronal loss increased with later Braak α-synuclein stages but did not vary across consecutive Braak α-synuclein stages. We observed a negative correlation between neuronal density and local α-synuclein burden in the substantia nigra of Parkinson's disease patients (ρ = -0.54), but no relationship with Hoehn & Yahr stage or disease duration. In conclusion, our findings cast doubt on the pathogenic role of α-synuclein aggregates in elderly, but do suggest that the severity of neurodegeneration and local burden of α-synuclein pathological conditions are closely coupled during disease progression in Parkinson's disease.
DOI: 10.1002/mds.25952
PubMed: 24996051
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000456
Links to Exploration step
pubmed:24996051Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.</title><author><name sortKey="Dijkstra, Anke A" sort="Dijkstra, Anke A" uniqKey="Dijkstra A" first="Anke A" last="Dijkstra">Anke A. Dijkstra</name><affiliation wicri:level="1"><nlm:affiliation>Department of Anatomy and Neurosciences, section of Functional Neuroanatomy, VU University Medical Center, Amsterdam, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Department of Anatomy and Neurosciences, section of Functional Neuroanatomy, VU University Medical Center, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Voorn, Pieter" sort="Voorn, Pieter" uniqKey="Voorn P" first="Pieter" last="Voorn">Pieter Voorn</name></author><author><name sortKey="Berendse, Henk W" sort="Berendse, Henk W" uniqKey="Berendse H" first="Henk W" last="Berendse">Henk W. Berendse</name></author><author><name sortKey="Groenewegen, Henk J" sort="Groenewegen, Henk J" uniqKey="Groenewegen H" first="Henk J" last="Groenewegen">Henk J. Groenewegen</name></author><author><name sortKey="Rozemuller, Annemieke J M" sort="Rozemuller, Annemieke J M" uniqKey="Rozemuller A" first="Annemieke J M" last="Rozemuller">Annemieke J M. Rozemuller</name></author><author><name sortKey="Van De Berg, Wilma D J" sort="Van De Berg, Wilma D J" uniqKey="Van De Berg W" first="Wilma D J" last="Van De Berg">Wilma D J. Van De Berg</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24996051</idno><idno type="pmid">24996051</idno><idno type="doi">10.1002/mds.25952</idno><idno type="wicri:Area/PubMed/Corpus">000456</idno><idno type="wicri:Area/PubMed/Curation">000456</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.</title><author><name sortKey="Dijkstra, Anke A" sort="Dijkstra, Anke A" uniqKey="Dijkstra A" first="Anke A" last="Dijkstra">Anke A. Dijkstra</name><affiliation wicri:level="1"><nlm:affiliation>Department of Anatomy and Neurosciences, section of Functional Neuroanatomy, VU University Medical Center, Amsterdam, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Department of Anatomy and Neurosciences, section of Functional Neuroanatomy, VU University Medical Center, Amsterdam</wicri:regionArea></affiliation></author><author><name sortKey="Voorn, Pieter" sort="Voorn, Pieter" uniqKey="Voorn P" first="Pieter" last="Voorn">Pieter Voorn</name></author><author><name sortKey="Berendse, Henk W" sort="Berendse, Henk W" uniqKey="Berendse H" first="Henk W" last="Berendse">Henk W. Berendse</name></author><author><name sortKey="Groenewegen, Henk J" sort="Groenewegen, Henk J" uniqKey="Groenewegen H" first="Henk J" last="Groenewegen">Henk J. Groenewegen</name></author><author><name sortKey="Rozemuller, Annemieke J M" sort="Rozemuller, Annemieke J M" uniqKey="Rozemuller A" first="Annemieke J M" last="Rozemuller">Annemieke J M. Rozemuller</name></author><author><name sortKey="Van De Berg, Wilma D J" sort="Van De Berg, Wilma D J" uniqKey="Van De Berg W" first="Wilma D J" last="Van De Berg">Wilma D J. Van De Berg</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>Case-Control Studies</term><term>Cell Count</term><term>Cell Death</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Lewy Body Disease (pathology)</term><term>Male</term><term>Netherlands</term><term>Neurons (metabolism)</term><term>Neurons (pathology)</term><term>Parkinson Disease (pathology)</term><term>Severity of Illness Index</term><term>Statistics as Topic</term><term>Substantia Nigra (pathology)</term><term>alpha-Synuclein (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Netherlands</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lewy Body Disease</term><term>Neurons</term><term>Parkinson Disease</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>Case-Control Studies</term><term>Cell Count</term><term>Cell Death</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Severity of Illness Index</term><term>Statistics as Topic</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Pays-Bas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To gain a better understanding of the significance of α-synuclein pathological conditions during disease progression in Parkinson's disease, we investigated whether 1) nigral neuronal loss in incidental Lewy body disease and Parkinson's disease donors is associated with the local burden α-synuclein pathological conditions during progression of pathological conditions; 2) the burden and distribution of α-synuclein pathological conditions are related to clinical measures of disease progression. Post-mortem tissue and medical records of 24 Parkinson's disease patients, 20 incidental Lewy body disease donors, and 12 age-matched controls were obtained from the Netherlands Brain Bank for morphometric analysis. We observed a 20% decrease in nigral neuronal cell density in incidental Lewy body disease compared with controls. Nigral neuronal loss (12%) was already observed before the appearance α-synuclein aggregates. The progression from Braak α-synuclein stage 3 to 4 was associated with a significant decline in neuronal cell density (46%). Nigral neuronal loss increased with later Braak α-synuclein stages but did not vary across consecutive Braak α-synuclein stages. We observed a negative correlation between neuronal density and local α-synuclein burden in the substantia nigra of Parkinson's disease patients (ρ = -0.54), but no relationship with Hoehn & Yahr stage or disease duration. In conclusion, our findings cast doubt on the pathogenic role of α-synuclein aggregates in elderly, but do suggest that the severity of neurodegeneration and local burden of α-synuclein pathological conditions are closely coupled during disease progression in Parkinson's disease.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24996051</PMID><DateCreated><Year>2014</Year><Month>09</Month><Day>11</Day></DateCreated><DateCompleted><Year>2015</Year><Month>05</Month><Day>14</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>1244-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.25952</ELocationID><Abstract><AbstractText>To gain a better understanding of the significance of α-synuclein pathological conditions during disease progression in Parkinson's disease, we investigated whether 1) nigral neuronal loss in incidental Lewy body disease and Parkinson's disease donors is associated with the local burden α-synuclein pathological conditions during progression of pathological conditions; 2) the burden and distribution of α-synuclein pathological conditions are related to clinical measures of disease progression. Post-mortem tissue and medical records of 24 Parkinson's disease patients, 20 incidental Lewy body disease donors, and 12 age-matched controls were obtained from the Netherlands Brain Bank for morphometric analysis. We observed a 20% decrease in nigral neuronal cell density in incidental Lewy body disease compared with controls. Nigral neuronal loss (12%) was already observed before the appearance α-synuclein aggregates. The progression from Braak α-synuclein stage 3 to 4 was associated with a significant decline in neuronal cell density (46%). Nigral neuronal loss increased with later Braak α-synuclein stages but did not vary across consecutive Braak α-synuclein stages. We observed a negative correlation between neuronal density and local α-synuclein burden in the substantia nigra of Parkinson's disease patients (ρ = -0.54), but no relationship with Hoehn & Yahr stage or disease duration. In conclusion, our findings cast doubt on the pathogenic role of α-synuclein aggregates in elderly, but do suggest that the severity of neurodegeneration and local burden of α-synuclein pathological conditions are closely coupled during disease progression in Parkinson's disease.</AbstractText><CopyrightInformation>© 2014 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dijkstra</LastName><ForeName>Anke A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurosciences, section of Functional Neuroanatomy, VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voorn</LastName><ForeName>Pieter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Berendse</LastName><ForeName>Henk W</ForeName><Initials>HW</Initials></Author><Author ValidYN="Y"><LastName>Groenewegen</LastName><ForeName>Henk J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><CollectiveName>Netherlands Brain Bank</CollectiveName></Author><Author ValidYN="Y"><LastName>Rozemuller</LastName><ForeName>Annemieke J M</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>van de Berg</LastName><ForeName>Wilma D J</ForeName><Initials>WD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000704">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002452">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016923">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020961">Lewy Body Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009426">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013223">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013378">Substantia Nigra</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051844">alpha-Synuclein</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Braak α-synuclein staging</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">substantia nigra</Keyword><Keyword MajorTopicYN="N">α-synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24996051</ArticleId><ArticleId IdType="doi">10.1002/mds.25952</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000456 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000456 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24996051
|texte= Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24996051" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |